Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06630481
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-10-02
Brief Title:
Long-term Survival Outcomes According to the Pathologic Response After Neoadjuvant Treatment in PDAC and the Fate of the Patients with Good CAP Grade
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Long-term Survival Outcomes According to the Pathologic Response After Neoadjuvant Treatment in PDAC and the Fate of the Patients with Good CAP Grade
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CAP with NAT
Brief Summary:
1 Neoadjuvant treatment NAT is increasingly used in managing pancreatic ductal adenocarcinoma PDAC necessitating dependable methods to evaluate tumor response
2 Among various pathological tumor regression grading systems the College of American Pathologists CAP system is commonly used to predict chemo-responsiveness and survival
3 This study aimed to analyze long-term survival outcomes based on pathologic response using the CAP grade after NAT in PDAC and to identify clinicopathologic factors that influence a favorable pathologic response
2 Among various pathological tumor regression grading systems the College of American Pathologists CAP system is commonly used to predict chemo-responsiveness and survival
3 This study aimed to analyze long-term survival outcomes based on pathologic response using the CAP grade after NAT in PDAC and to identify clinicopathologic factors that influence a favorable pathologic response
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None